ClinicalTrials.gg
RecruitingNCT06936943Updated Feb 13, 2026

ONO-4538 Study in Patients With Richter's Transformation

A Phase 2 interventional study of ONO-4538 in Richter's Transformation, sponsored by Ono Pharmaceutical Co., Ltd.. Recruiting at 10 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Investigate the efficacy and safety of ONO-4538 in patients with Richter's transformation

02

Conditions studied

  • Richter's Transformation
03

In context

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of diffuse large B-cell lymphoma (DLBCL)-type or Hodgkin lymphoma(HL)-type Richter's transformation with a history of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
  • In the case of DLBCL-type Richter's transformation, , intolerant or ineligible for treatment of DLBCL
  • Patients with
  • (ECOG) performance status of 0 or 1
  • Expected to survive for 90 days or more

Exclusion criteria

Exclusion Criteria:

  • Serious complications
  • Active multiple cancers
  • Active central nervous system (CNS) disease
  • History of hematopoietic stem cell transplantation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    ONO-4538

    ONO-4538 480 mg solution administered intravenously every 4 weeks

    Drug: ONO-4538

Interventions

  • every 4 weeks

    Also known as: Nivolumab, Opdivo

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) (Centralized assessment)

    Time frame: up to 4 years

Secondary outcomes

  1. Objective response rate (ORR) (site investigator assessment)

    Time frame: up to 4 years

  2. Overall survival (OS)

    Time frame: up to 4 years

  3. Progression free survival (PFS)

    Time frame: up to 4 years

  4. Disease control rate (DCR)

    Time frame: up to 4 years

  5. Duration of response (DOR)

    Time frame: up to 4 years

  6. Time to response (TTR)

    Time frame: up to 4 years

  7. Best overall response (BOR)

    Time frame: up to 4 years

  8. Change rate from baseline in the sum of diameters (SPD) of target lesions

    Time frame: up to 4 years

  9. Best change rate from baseline in the sum of diameters (SPD) of target lesions

    Time frame: up to 4 years

  10. Improvement rate of B symptom

    Time frame: up to 4 years

  11. Safety (Adverse event)

    Time frame: Up to 30 days after the last dose

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jul 2029, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2025
First posted
Apr 20, 2025
StartActual
Nov 19, 2025
Primary completionEst.
Jul 31, 2029
CompletionEst.
Jul 31, 2030
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06936943
Responsible party
Sponsor
First posted
Apr 20, 2025
Start date
Nov 19, 2025
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2030 (estimated)
Last update
Feb 13, 2026

Study contacts

North America Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+18665877745(Toll-Free)
International Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+17162141777(Standard)
Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion